Leukemia Clinical Trials in Ohio

Showing 701-720 of 873 trials

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01130506

This phase I trial studies the side effects and the best dose of cytarabine when given together with decitabine and vorinostat in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has returned or has not responded to treatment. Drugs used in chemotherapy, such as cytarabine and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cytarabine together with decitabine and vorinostat may kill more cancer cells.

Previously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia+3 more

National Cancer Institute (NCI)17 participantsStarted May 2010

Columbus, Ohio, United States • Houston, Texas, United States

COMPLETED32 miles

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

NCT00437060

This clinical trial is looking at brain function in young patients receiving methotrexate for acute lymphoblastic leukemia. Learning about the long-term effects of methotrexate on brain function may help doctors plan cancer treatment.

Childhood B Acute Lymphoblastic LeukemiaChildhood T Acute Lymphoblastic LeukemiaCognitive Side Effects of Cancer Therapy+4 more

Children's Oncology Group233 participantsStarted Jan 2007

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Downey, California, United States +109 more locations

PreviousPage 36 of 44Next

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia

Leukemia Trials in Other Cities

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Weaning And Variability Evaluation

Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies

The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients

Evaluating Processes of Care & the Outcomes of Children in Hospital (EPOCH)

Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

CNDO-109-AANK for AML in First Complete Remission (CR1)

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Other Conditions in Ohio